Home > Cardiology > ACC 2022 > Heart Failure and Cardiomyopathy > Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF

Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF

Presented By
Prof. Michael Felker, Duke Clinical Research Institute, USA
Conference
ACC 2022
Trial
Phase 3, METEORIC-HF
The multicentre, randomised, phase 3 METEORIC-HF trial reported that the cardiac myosin activator omecamtiv mecarbil did not improve exercise capacity over 20 weeks in heart failure patients with reduced ejection fraction (HFrEF). Prof. Michael Felker (Duke Clinical Research Institute, NC, USA) presented the METEORIC-HF results (NCT03759392), which come 18 months after omecamtiv mecarbil showed mixed results in the GALACTIC-HF trial [1,2]. Although GALACTIC-HF did meet its primary objective of reducing cardiovascular death or heart failure events compared with placebo, the top-line mortality data did not support overall clinical benefit [2]. Given the substantial day-to-day functional limita...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on